An observational study in Sepsis and Severe Bacterial Infections, sponsored by University Hospital, Rouen. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by University Hospital, Rouen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Sepsis with a site in France — 41 open to participants now, 46 under way, 5 of them phase 3. Sepsis · France.
Among the 209 studies in Sepsis with a site in France, this one is the 90th largest by planned enrollment of the 97 observational ones that give a count, is one of 10 that started in 2025, is one of 97 observational ones, reaches primary completion later than 29 of the 45 other live ones, and was the 195th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →41 of the 209 studies in Sepsis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Bordeaux · Sites in France
Ages 18+
Deepull Diagnostics S.L. · Sites in France, United States, Germany and 2 more countries
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 37 wk+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 31 · Phase 4 10
First in 1997; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 150 across the 111 interventional studies, 170 across the 97 observational. Of the 140 that completed or were terminated, 13 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 209 have an industry lead sponsor. The 10 most frequent:
University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.
University Hospital, Rouen has 6 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
13 of the studies in Sepsis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05843786Phase 3Hospices Civils de LyonHuman Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients | 2027-07-30 |
| NCT07085624Centre Hospitalier Universitaire de Saint EtienneEarly Optimization of Ceftazidime Regimen in Critical Care | 2026-11 |
| NCT06854640BayerA Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy | 2026-12-25 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
| NCT07144917Hospices Civils de LyonImmunoparalysis After Pancreaticoduodenectomy | 2027-03-18 |
Add all 13 to your calendar (.ics) → With an account.
Among the 209 studies in Sepsis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severe bacterial infections, often responsible for sepsis and septic shock, are a major challenge in critical care: approximately 50% of patients are affected, with a mortality rate of up to 40%. Their initial management consists of antibiotic therapy with an adapted spectrum of activity and dose. One of the most widely used antibiotic therapies in intensive care is the piperacillin-tazobactam (pip-taz) combination, a beta-lactam combined with a beta-lactamase inhibitor, which is indicated probabilistically in many infections (pneumopathies, intra-abdominal infections, urinary tract infections, etc.). Mortality rates of up to 40%. Their initial management consists of antibiotic therapy with an appropriate spectrum of activity and dose. One of the most widely used antibiotic therapies in intensive care is the piperacillin-tazobactam (pip-taz) combination, a beta-lactam combined with a beta-lactamase inhibitor, which is indicated probabilistically in many infections (pneumonia, intra-abdominal infections, urinary tract infections, etc.).
Intensive care patients with septic shock exhibit specific pharmacokinetics with an increased volume of distribution, notably due to significant capillary leakage, often disrupted hepatic metabolism, possible hypoalbuminemia, the presence of renal hyperclearance in the initial phase or conversely, the onset of renal failure with altered glomerular filtration rate, sometimes leading to extrarenal clearance, changes that have consequences for the efficacy and toxicity of the administered antibiotic therapy. Sepsis itself also causes renal dysfunction, with the main pathophysiological hypotheses being an alteration of microcirculation, cellular metabolic reprogramming, and deregulation of the inflammatory response. It is therefore essential to focus on the dosages administered and the pharmacokinetics of these patients. Indeed, underdosing is associated with the emergence of resistance and a poorer prognosis in intensive care patients: increased risk of treatment failure, length of stay and mortality. Conversely, significant overdoses can be associated with a poorer renal prognosis, seizures, encephalopathy which can lead to delayed awakening, prolonged duration of mechanical ventilation and intensive care stay.
Pip-taz is administered intravenously due to non-absorption via the oral route. It is weakly bound to plasma proteins (21%), inducing good clearance of extrarenal clearance (fraction extracted in 4 hours: 23.6% of the administered dose). Its plasma half-life is 60 minutes. This molecule is not metabolized, and is therefore independent of liver function. It is eliminated mainly in active form in the urine (65%) and bile (35%). Thus, the main determinant of pip-taz clearance is renal clearance, or continuous extrarenal clearance (CER) in dialysis patients in intensive care.
Pip-taz is characterized by time-dependent pharmacodynamics, with better coverage with continuous infusions compared to discontinuous infusions. However, there is no well-defined pattern in patients undergoing continuous extra-renal purification. Despite recommendations regarding antibiotic dosages for use in intensive care, the lack of data regarding patients undergoing continuous renal replacement therapy (CRRE) remains a major and complex problem in optimizing treatment, as these patients present with unique pharmacokinetics, with an increased risk of treatment failure and mortality. Furthermore, there has been a change in practices in recent years, with pip-taz being administered by continuous infusion and increasingly less by discontinuous infusion, in accordance with the latest recommendations.
To our knowledge, few studies have examined the pharmacokinetics of the pip-taz combination in patients undergoing cCRRE in intensive care. Most of these rare studies did not use standard pip-taz dosages, did not examine the clinical and biological variables influencing pip-taz clearance, and none have examined the impact of any preserved diuresis. Furthermore, there are no data on the kinetics of tazobactam in this population. It therefore seems relevant, given the frequent use of this antibiotic therapy in patients undergoing cERE, to accurately assess the clearance of piperacillin and tazobactam in this population. From a precision medicine perspective, these data could contribute to the construction of a pharmacokinetic model using a population approach, based on blood, urine, and effluent samples, in order to provide a tool to assist in the prescription of this antibiotic therapy in intensive care to reduce iatrogenicity and optimize its effectiveness.
Patients undergoing continuous extra-renal purification (CER) in the various intensive care units of the Rouen University Hospital (surgical, medical, cardiac surgical), receiving concomitant antibiotic therapy with piperacillin-tazobactam (initiated before or after CER) for sepsis or septic shock.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The concentration of piperacillin and tazobactam will be quantified by liquid chromatography coupled with tandem mass spectrometry (HPLC-MS² - CIC-CRB 1404) at each of these times by transposition of the method already used in current practice.
Determination of continuous extrarenal clearance (CERC) of piperacillin in patients with infection in intensive care
The cERC clearance of piperacillin will depend on the type of cERC used, thus determining a clearance: * diffusion (dialysis, continuous venomous hemodialysis (CVVHD)), * convection (filtration, continuous venomous hemofiltration (CVVH)), * diffusion and convection (dialysis and filtration, continuous venomous hemodiafiltration (CVVHDF)). Each of these clearances will be characterized by different formulas, based on the collection of the following parameters: pre- and post-filter concentrations, concentration in the dialysate/filtrate/effluent, cERC flow rate for diffusion and convection, hematocrit, and partition coefficient of the substance between whole blood and plasma.
Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)
Determination of EERc clearance of tazobactam
The cERC clearance of tazobactam will depend on the type of cERC used, thus determining a clearance: - diffusion (dialysis, continuous venomous hemodialysis (CVVHD)), - convection (filtration, continuous venomous hemofiltration (CVVH)), - diffusion and convection (dialysis and filtration, continuous venomous hemodiafiltration (CVVHDF)). Each of these clearances will be characterized by different formulas, based on the collection of the following parameters: pre- and post-filter concentrations, concentration in the dialysate/filtrate/effluent, cERC flow rate for diffusion and convection, hematocrit, and partition coefficient of the substance between whole blood and plasma.
Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)
Evaluation of total clearance of piperacillin in patients with preserved residual diuresis.
The total clearance (CLT) of piperacillin will be determined by considering that they correspond to the sum of the renal clearance (CLR) and the clearance of the EERc (CLEERc). Thus, CLT = CLR + CLEERc. In the absence of diuresis, CLR=0 will be considered and therefore CLT = CLEERc.
Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)
Evaluation of total clearance of tazobactam in patients with preserved residual diuresis.
The total clearance (CLT) of tazobactam will be determined by considering that they correspond to the sum of the renal clearance (CLR) and the clearance of the EERc (CLEERc). Thus, CLT = CLR + CLEERc. In the absence of diuresis, CLR=0 will be considered and therefore CLT = CLEERc.
Time frame: At Enrollment visit, Time 15 minutes, 30 minutes and 45 minutes, Time 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, 24 hours and 36 hours in pre-filter (before pre-dilution when present), post-filter (after post-dilution when present)
Description of the evolution of plasma concentrations of piperacillin over time.
Plasma concentrations of piperacillin over time will be evaluated using a population pharmacokinetic model using a nonlinear mixed-effects regression model.
Time frame: At 36 hours
Description of the evolution of plasma concentrations of tazobactam over time.
Plasma concentrations of tazobactam over time will be evaluated using a population pharmacokinetic model using a nonlinear mixed-effects regression model.
Time frame: At 36 hours
Development of a dosage regimen to optimize the benefit/risk balance
A dosage regimen to optimize the benefit/risk balance in this population will be developed by plotting the probability curves of reaching the therapeutic target (PTA) as a function of increasing MICs. The pharmacodynamic indices of efficacy retained will be the fraction of time where the free piperacillin concentration is greater than 1x the MIC (fT \> 1xMIC = 100%) and 4x the MIC (fT \> 4xMIC = 100%).
Time frame: At 36 hours
Plan to share: No — The data provided will be the property of the sponsor and will be used solely for its own research activities.
No publications or documents are linked to this record.
Start is estimated for Oct 2025; primary completion for Oct 2027, 24 months later.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 24 months is below that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.